ArticleScientific reports2026
TTF2 as a potential biomarker and immunotherapy target in glioma diagnosis and prognosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Glioma is one of the common brain tumors in the central nervous system, with a poor prognosis and a serious threat to the life and health of patients. Exploring effective prognostic markers and conducting in-depth studies on related molecular mechanisms are of great significance for improving the prognosis of glioma patients. TTF2 (Transcription Termination Factor 2) has initially demonstrated its value as a potential prognostic factor in various cancers. However, its specific role in glioma remains unclear. Materials and methods We evaluated the expression preference, prognostic value and clinical characteristics of TTF2 from the Tumor Genome Atlas (TCGA) database and the Chinese Glioma Genome Atlas (CGGA) dataset. We constructed clinical prognostic models using independent prognostic risk factors and TTF2, and evaluated the accuracy of the models using calibration curves. The biological functions of TTF2 were explored by GO/KEGG/GSEA enrichment analysis. The relationship between TTF2 expression and immune infiltration was analyzed by ssGSEA (Single Sample Gene Set Enrichment Analysis), and the expression of TTF2 mRNA in glioma samples was verified by tissue specimens. Result TTF2 was highly expressed in glioma. Multivariate analysis showed that TTF2 mRNA expression was an independent prognostic factor for Overall survival rate (OS) (HR = 2.113, 95%CI:1.393–3.204). Effective prognostic models can be constructed by using WHO classification, IDH status, age and the expression level of TTF2. Enrichment analysis and GSEA analysis showed that the expression of TTF2 was related to the production of immunoglobulins, adaptive immune responses, immune regulation, and the transmission of immune cell signaling factors, etc. ssGSEA showed that the expression of TTF2 was positively correlated with the infiltration level of Th2 cells. Conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.